Brief: Ventyx Biosciences Reports Clinical Data For Its Nlrp3 Inhibitor Portfolio And Provides Pipeline Updates At Virtual Investor Event

Ventyx Biosciences

11/03/2024 11:46

March 11 (Reuters) - Ventyx Biosciences Inc  VTYX.O :
    * VENTYX BIOSCIENCES REPORTS CLINICAL DATA FOR ITS NLRP3
INHIBITOR
PORTFOLIO AND PROVIDES PIPELINE UPDATES AT VIRTUAL INVESTOR
EVENT
    * VENTYX BIOSCIENCES INC - VTX3232 WAS WELL-TOLERATED IN
PHASE 1
TRIAL WITH ROBUST TARGET COVERAGE ACHIEVED IN BOTH PLASMA AND
CSF
    * VENTYX BIOSCIENCES INC -PLANNING TO INITIATE PHASE 2A
TRIALS IN
PARKINSON'S DISEASE AND OBESITY IN H2 2024
    * VENTYX BIOSCIENCES INC -EXPECTS ITS CURRENT CASH, CASH
EQUIVALENTS AND MARKETABLE SECURITIES TO FUND PLANNED OPERATIONS
INTO AT LEAST H2 2026
    * VENTYX BIOSCIENCES INC - TOPLINE PHASE 2 DATA FOR VTX2735
IN
CAPS PATIENTS ESTABLISH CLINICAL PROOF OF CONCEPT
    * VENTYX BIOSCIENCES INC - VENTYX IS PLANNING TO EVALUATE
VTX2735
IN CARDIOVASCULAR DISEASES
    * VENTYX BIOSCIENCES INC - REPORTED CASH, CASH EQUIVALENTS
AND
MARKETABLE SECURITIES OF $252.2 MILLION AS OF DECEMBER 31, 2023.

Source text for Eikon:  ID:nGNX63x8j3 
Further company coverage:  VTYX.O 

 ((Reuters.Briefs@thomsonreuters.com;))